E2F3 and acute myeloid leukemia: In 2010, Pulikkan et al. showed that miR-34a blocks myeloid proliferation by targeting E2F3 during granulopoiesis, but it is downregulated in AML with mutations affecting the CCAAT enhancer binding protein alpha (C/EBPα).